From the Editor: A Note on the 2020 Redesign
Editor-in-Chief, Dr. Laura Michaelis introduces the 2020 The Hematologist print redesign, including a better layout, more modern look, and clearer signposts within
A Novel Immunotherapy for T-ALL
Drs. Diorio and Teachey discuss the work of researchers that developed two monoclonal antibodies targeting IL-7Rα that proved effective when used separately or in combinati
Download issue as PDF
Dr. LeBlanc and Dr. Litzow take a look at an issue within the field consisting of hematologists referring their patients to hospice late or not at all even when there are so many proven benefits to this type of high-quality end-of-life care.
Dr. Teachey reviews a study that suggests that patients in morphologic remission but with high minimal residual disease have inferior outcomes.
Dr. DeBaun discusses a study that presents strong evidence that sickle cell trait is not associated with ischemic stroke.
Dr. Kim discusses a study that demonstrates the relevance of molecular minimal residual disease by next-generation sequencing in acute myeloid leukemia.
Dr. Malpica Castillo and Dr. Moll provide recommendations to guide hematologists' approach to using a new herpes zoster vaccine.
Dr. Moss reviews a study that demonstrates the success of using gene therapy for the genetic correction of thalassemia.
Dr. Keel discusses a study that addresses uncertainties about antiphospholipid antibody testing and duration of anticoagulation decisions in unprovoked venous thromboembolism.
Dr. Linkins looks at evidence that demonstrates that aspirin is as effective as oral anticoagulant rivaroxaban post hip and knee arthroplasty in a significant subset of patients.
Dr. Jacobson discusses a study that compares AVD+brentuximab and ABVD as first-line treatment of advanced-stage Hodgkin lymphoma.
Dr. Abdel-Wahab looks at several studies that show different ways to reactivate wild-type p53 as a therapeutic option in leukemia and other forms of cancer.
Dr. Sweet presents the case of a 48-year-old woman with chronic-phase chronic myeloid leukemia being treated effectively with imatinib, and contemplates whether the patient is a candidate for a trial of tyrosine kinase inhibitor cessation.
Dr. Jenny Despotovic covers the expanded therapeutic repertoire currently emerging to treat immune thrombocytopenia (ITP) as understanding of ITP disease biology improves.
Drs. Sklavenitis Pistofidis and Ghobrial discuss a study that looks at a targeted approach to therapy for multiple myeloma patients carrying a t(1;14) translocation.
Drs. Doug Engel and Doug Higgs pay tribute to hematologist George Stamatoyannopoulos, MD, recalling his work in the field of biomedical research of blood and its disorders.
Dr. Thompson discusses ASH's advocacy efforts in support of programs and policies that enable the Society to deliver change to patients and their families worldwide.
Dr. Kenneth Todd Moore comments on Contributing Editor Dr. Stephan Moll's article on the use of direct oral anticoagulants in patients on hemodialysis.
In this Image Challenge, Dr. Venkataraman and Dr. Sir Philip look at a 65-year-old patient with syncope and mild hepatosplenomegaly whose blood count results prompted a bone marrow biopsy. Take a look at the bone marrow biopsy and blood smear to determine the diagnosis.
September-October 2019Volume 16, Issue 5
A new Compendium providing updated clinical information to "Ask the Hematologist" articles published in The Hematologist from 2010 to 2015 is now available.
AMERICAN SOCIETY OF HEMATOLOGY
2021 L Street NW, Suite 900, Washington, DC 20036
Phone 202-776-0544 | Fax 202-776-0545
by American Society of Hematology